Temasek invests US$250m in China health care venture
[SINGAPORE] Temasek Holdings Pte is investing US$250 million in the China operations of Columbia Pacific Management, as Singapore's state-owned investment firm expands its health care holdings.
Temasek and Columbia will form a 50-50 joint venture aimed at providing China's growing middle-class population with affordable health care services, Seattle-based Columbia said in a statement.
The partnership will enable Columbia China to further expand in China through acquisitions and new projects, according to the statement.
During its latest financial year ended March 31, Temasek loaded up on stakes in US pharmaceutical and health-care firms including Alexion Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc, which develop treatments for serious medical conditions.
The share of life sciences and agriculture-related assets in Temasek's portfolio has doubled to 4 per cent in the two years ending March 31, according to its website.
BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Economy & Policy
US-Singapore FTA marks 20 years: a bridge ‘at the right place, right time’
Singapore’s employment growth eases in Q1, as tighter foreign worker quotas kick in for construction firms
Daily Debrief: What Happened Today (Apr 30)
Biden’s ‘worker-centred trade policy’ involves building ‘tripartism’: US trade chief
Daily Debrief: What Happened Today (Apr 29)
NTUC to help workers develop skills, adapt to new job opportunities